SAINTE-FOY, QUEBEC -- (MARKET WIRE) -- December 20, 2006 -- Bioxel Pharma Inc. (TSX VENTURE: BIP), a leading manufacturer and supplier of taxane APIs and developer of targeted oncology drugs, is pleased to announce that the Corporation has achieved a critical milestone by producing docetaxel API at pre-industrial scale using its patented semi-synthetic process.
